On GLP-1 medicines it is expected: every trial curve drops quickly at first, slows and then levels off. A 2025 analysis of the tirzepatide trial SURMOUNT-1 defined a plateau as a weight change of less than 5% over a 12-week interval and every 12-week interval after it.1
What counts as a plateau
That research definition has two features that are easy to miss. It looks at 12 weeks, not one or two, so a fortnight without movement on the scale does not come close to it. And its threshold is wide: 5% of body weight in 12 weeks is a real amount, about 10 pounds for someone weighing 200 pounds.1 By that definition, a plateau is a slowdown, not a stop, and a week or two of the same number on the scale says very little on its own.
Slow is not stopped
In SURMOUNT-1, the people who reached their plateau earliest, by week 24, had lost 12.1% of their weight at that point. By week 72 the same people were down 15.4%: another 3.3 points over the 48 weeks after the plateau began.1 People on higher doses plateaued later and at a greater loss. By week 24, a plateau had begun in 44% of people on 5 mg, 32% on 10 mg and 24% on 15 mg; by week 72, 27%, 33% and 40% had still not reached one.1 For someone who started at 230 pounds, 3.3 points is about 8 pounds more, by our arithmetic.
The withdrawal trial SURMOUNT-4 shows the same slow tail: people who had lost 20.9% in 36 weeks and stayed on tirzepatide lost a further 5.5% over the next year.2
Why weight levels off
A 2024 modelling study by Kevin Hall fitted a model of energy balance to the average weight curves of dieting, semaglutide 2.4 mg, tirzepatide 10 mg and gastric bypass. The model has two dials: how hard the treatment pushes food intake down, and how strongly appetite climbs back as weight falls. Dieting leaves that push-back at full strength, so the loss stops early. The two drugs and the surgery "substantially weakened the appetite feedback control circuit", which stretches out the period of loss before the plateau.3 The drug turns the push-back down rather than removing it, so a level is reached eventually.
Dose sets the level
In the Zepbound trial, the 10 mg and 15 mg doses differed by 1.4 points of weight loss.4 In one trial that stepped people down from 10 or 15 mg to 5 mg, they settled at a 16.6% loss a year later, against 21.9% for those who stayed on the higher dose.5 That is evidence, within one group of people, that the dose helps set where weight settles.
Slow starters
A plateau is different from a slow start. Of the people who had lost under 5% at week 12 on tirzepatide, 70% passed 5% by week 24 and 90% by week 72. The analysis concluded that extending treatment well beyond 12 weeks may let more people reach meaningful weight loss.6 Late responders were more often men and heavier at the start.6
What the label means by long term
The Zepbound label describes two jobs in one sentence: to reduce excess body weight and to maintain weight reduction long term.4 The first job has a natural end; the plateau is where the second begins. Our page on the Zepbound plateau has a calculator for checking your own 12-week trend.
Sources
- Horn DB, Kahan S, Batterham RL, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes 2025;15:e12734. doi:10.1111/cob.12734
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
- Hall KD. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity (Silver Spring) 2024;32:1163-1168. doi:10.1002/oby.24027
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2.1, 6.1, 12.1, 12.2 and 14.1 (Table 2, Figure 3). accessdata.fda.gov
- Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet 2026;407:2305-2318. doi:10.1016/S0140-6736(26)00656-2
- Ard J, Lee CJ, Gudzune K, et al. Weight reduction over time in tirzepatide-treated participants by early weight loss response: post hoc analysis in SURMOUNT-1. Diabetes Obes Metab 2025;27:5064-5071. doi:10.1111/dom.16554
Related analyses
Zepbound plateau: when weight loss slows, why, and what the trials show
Wegovy weight loss chart: the trial results week by week, in your own weight
Zepbound dosing schedule: every step from 2.5 to 15 mg, with your dates
What to eat on a GLP-1: the priorities of four medical societies, with a day you can build
Log your weight weekly and see 12-week trends instead of single days.
Open Dose Insider